Research: Clinical Tests
Oral Toxicity Test
Classified as Orally Non-Toxic: There were no abnormal findings. The results indicate Bio-Safe® Skin Shield™ lotion is orally non-toxic - even at a dose level that would be lethally toxic to 50% of the subjects. Test performed by AMA Laboratories, Inc.
Eye Irritation Test (Draize Test)
Classified as Non-Irritating: Bio-Safe® Skin Shield™ lotion was non-irritating, with no irritation in any of the areas of the eye on any of the subjects (all scores of "0"). Test performed by AMA Laboratories, Inc.
Bacterial Inhibitions
Pathogenic Tests for Bio-Safe® Skin Shield™ lotion: E.coli, Enterobacter, Pseudomonas aeruginosa, Klebsiella, Micrococcus, Proteus, Serratia marcescens, Staphylococcus aureus, MRSA, Salmonella typhi, Streptococcus pyogenes, Listeria monocytogenes, Shigella dysenteriae, and Shigella sonnei. Inhibition of growth was clearly shown in all of the bacteria tested.
Repeat Insult Patch Test
Classified as Non-Irritating and Non-Sensitizing: No adverse reactions were reported during this dermatological study. Test performed by International Research Services, Inc.
Antibacterial Action of Bio-Safe® Skin Shield™ Lotion
Immediate Antibacterial Protection on Skin: Bio-Safe® Skin Shield™ lotion's polymer coating on the skin killed 80-97% of pathogens in seconds and even four hours later.
Bio-Safe® Skin Shield™ Lotion Antibacterial Residue Test
Reduction of Bacteria Counts: A modified glove-juice test demonstrated a reduction of bacteria counts three hours following treatment of the hands.
Dermal Absorption of MEK Test
Absorbed Less MEK: Mocon Labs found there was 740 times less MEK absorbed through skin threated with Bio-Safe® Skin Shield™ lotion than with untreated skin.
Infection Control Study
Infections and Sick Days Decrease: Healthcare workers using Bio-Safe® Skin Shield™ lotion on a regular basis had over a 50% decrease in patient infections from the previous year. Flight attandants using Bio-Safe® Skin Shield™ lotion had a 7% decrease in the number of sick occurances and a 23.7% decrease in the number of sick days used compared to one and two years prior.
